Intellia Advances Gene-Editing Drug Toward Regulatory Acceptance
Intellia ended June with $628.4 million in cash and securities after an April stock offering.
Gene-editing drug developer Intellia Therapeutics (NTLA) advanced its lead therapy toward regulatory acceptance as its quarterly net loss widened and spending shifted toward commercial preparations.
Intellia expects the Food and Drug Administration to accept the rolling biologics license application for lonvoguran ziclumeran in the second half of 2026, a step beyond its earlier plan to complete the submission during that period. The targeted U.S. launch remains the first half of 2027.
Second-quarter collaboration revenue fell 46% to $7.7 million, primarily because of lower revenue from Regeneron. Net loss widened 5% to $106.6 million, while the loss narrowed to $0.80 a share from $0.98 as the weighted-average share count increased 29%.
The expense mix reflected the company's transition toward a potential commercial launch. Research-and-development expense declined 15% to $82.6 million on lower external costs for lead programs and reduced stock-based compensation, while general-and-administrative expense rose 39% to $37.8 million as Intellia built commercial infrastructure and incurred higher legal and stock-compensation costs.
Additional HAELO trial data strengthened the clinical profile supporting the lonvo-z application. The treatment reduced hereditary angioedema attacks requiring on-demand therapy by 89% and moderate or severe attacks by 91%, while producing a 17.04-point placebo-adjusted improvement in quality of life. Each result had a p-value below 0.0001.
Intellia also moved its launch preparations into execution, finalizing field medical, reimbursement and strategic-accounts teams and engaging U.S. hereditary angioedema treatment centers.
For nexiguran ziclumeran, the company reinitiated and advanced enrollment in the MAGNITUDE and MAGNITUDE-2 Phase 3 studies after resuming patient screening in the first quarter. Intellia expects MAGNITUDE-2 enrollment to finish in the second half of 2026. An analysis of more than 600 trial samples associated the highest liver-transaminase elevations with a specific HLA allele, leading the company to provide HLA-genotyping information to investigators and patients as it engages regulators.
Cash, cash equivalents and marketable securities increased $23.2 million from year-end after Intellia raised about $195 million net in an April public offering. The company's resources should fund operations at least into 2028, extending well beyond the anticipated lonvo-z launch and excluding any potential revenue from the therapy.